0082N0.KQ Kanaph Therapeutics Inc.

Healthcare Biotechnology KOSDAQ
9,100 KRW
Close of Oct 30, 2026
8,710 56,300
Market cap
KRW 119B
P/E
-
P/B
2.57x
ROE
-41.7%
Dividend yield
-
Fundamental score
0.5/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 0082N0.KQ undervalued?

Graham number

The Graham number of Kanaph Therapeutics Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Kanaph Therapeutics Inc. fundamental analysis

3 of 21 checks passed

ROE 0/2

Low return on equity (-41.7%), below 10%.

ROA 0/1

Return on assets (-40.0%) is below the industry median (-10.1%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share history is shorter than 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (-25.8%) is below the industry median (4.8%).

Revenue Growth 1/2

Revenue grew 1.9% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Cash Runway 0/2

Cash covers 0.8 years of the current cash burn.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 0/1

Price to book (2.6x) is above the industry median (2.4x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Kanaph Therapeutics Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Kanaph Therapeutics Inc.

Kanaph Therapeutics Inc., a biotech company, engages in drug development activities that include drug discovery and early-stage clinical trials in South Korea and the United States. The company's therapeutic platform includes bi-specific antibodies, Fc-fusions, and small molecules. It develops KNP-101, a FAP-targeted interleukin-12 cytokine, which is in preclinical stage for the treatment of solid tumors with an immunosuppressive tumor microenvironment; KKNP-301, a bispecifi…

Full company profile